Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

Neuroinflammation drives the progression of neurodegenerative disorders like Alzheimer's, Parkinson's, and multiple sclerosis. Targeting neuroinflammation with small molecules is promising, but ...

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine ...

The biosimilar market continued to grow, with 57 approved biosimilars and 17 reference product biologics as of June 2024. Biosimilars that have seen the fastest uptake have been in oncology, ...

BMB-201 demonstrated dose-dependent efficacy in pain modelsBMB-201 demonstrated similar efficacy to morphine in several pain modelsNEW YORK, Oct.

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Lipella Pharmaceuticals’ innovative liposomal drug delivery platform receives US patent: Pittsburgh Wednesday, October 16, 2024, 17:00 Hrs [IST] Lipella Pharmaceuticals Inc., a ...

His team analyzed literature on miRNA, summarizing the close relationship between these small molecules and cancer. miRNA is a type of non-coding RNA that does not encode proteins, but can target more ...

In recent years, the conversation surrounding natural supplements has gained considerable traction, with many seeking alternatives to traditional pharmaceuticals for pain relief, mental clarity, and ...